Novo Nordisk CEO Lars Fruergaard Jorgensen has been fielding calls from food company chief executives who have questions about the company's diabetes and weight-loss-related drugs. "They are scared ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

Amazon may be known for its retail and tech chops, but the company has also built a strong operation in the healthcare realm ...

BMO Capital lowered the firm’s price target on Novo Nordisk (NVO) to $105 from $156 but keeps an Outperform rating on the shares. The ...

Shares in Ozempic maker Novo Nordisk tumbled after an experimental anti-obesity shot fell short of expectations. The shares fell more than 20% in Copenhagen, closing at their lowest since August 2023.

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

FedEx, the shipping and logistics giant, plans to spin off its freight trucking business, Novo Nordisk sinks after disappointing obesity drug data, and Carnival rises after better-than-expected ...

Ifølge ham er aktiemarkedet en udfordrende størrelse, også for Novo Nordisk og andre medicinalfirmaer. - Tidligere var medicinalselskaberne en sikker havn, hvor privatinvestorerne kunne lune ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Novo Nordisk (NVO) stock dropped more than 15% on Friday following an update on its obesity drug that fell short of expectations. Headlines from the company’s press release revealed that Novo ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...